Biggest Gainer and Losers
- Published in Day Trading
Biggest movers
- Published in Day Trading
ADMA FDA Approval; Sangamo SGMO clinical update pre-market tomorrow
ADMA Biologics, Inc. (NASDAQ: ADMA) announced following the close of the after-hours session the FDA approved Asceniv (RI-002) for the treatment of Primary Humoral Immunodeficiency Disease Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced that management will host a conference call on Tuesday, April 2nd at 8a.m. Eastern Time to provide a clinical development update. No details were provided
- Published in Day Trading
After an amazing March, we should see a slower April.
Traders are most likely stuck holding stocks they should have sold days and weeks ago. It usually takes any 2 or 4 weeks for them to finally give up and sell thier positions at a loss. I expect the markets to be slower in April and back in May of 2019.
- Published in Day Trading
US STOCKS-Wall St rallies on upbeat China, U.S. manufacturing data
* Banks climb as U.S. yields hit 1-week high * Chipmakers rise on positive China data * Lyft drops below IPO price on second day of trading * Indexes up: Dow 1.27 pct, S&P 1.16 pct, Nasdaq 1.29 pct (Updates to market close) NEW YORK, April 1 (Reuters) – U.S. stocks rallied on Monday, starting
- Published in Day Trading
Bio recap
AERI FDA Approval +5%; Axovant AXGT offering Aerie Pharmaceuticals, Inc.(NASDAQ:AERI) announced after-hours Tuesday that the FDA approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Shares closed Wednesday up 5% to $47.97. Akari Therapeutics, Plc (Nasdaq: AKTX) shares, which were in nano-cap territory prior to today, closed
- Published in Day Trading
Immune Design IMDZ shares soar 310% on buyout by Merck MRK
Immune Design (NASDAQ:IMDZ) announced that it will be acquired by Merck(NYSE:MRK) for $5.85 per share in cash for an approximate value of $300m. Shares closed up 310% to $5.82. Zosano Pharma(NASDAQ:ZSAN) announced the completion of the second and final stage of the long-term safety trial for Qtrypta, in which patients treated migraine attacks over a one year period. The company noted
- Published in Day Trading
19 Best Stocks to Buy for 2019 (And 5 to Sell)
Getty Images Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock
- Published in Day Trading
7 Popular Technical Indicators and How to Use Them to Increase Your Trading Profits
Ever wondered how to use technical indicators in trading? Well wonder no more, this article introduces 7 popular indicators, and the strategies you can use to profit from their signals. Technical trading involves reviewing charts and making decisions based on patterns and indicators. These patterns are particular shapes that candlesticks form on a chart, and
- Published in Day Trading